Literature DB >> 32114685

Recent Research Advances in Renin-Angiotensin-Aldosterone System Receptors.

Kengo Azushima1,2, Norihiko Morisawa3, Kouichi Tamura2, Akira Nishiyama4.   

Abstract

PURPOSE OF REVIEW: The renin-angiotensin-aldosterone system (RAAS) plays important roles in regulating blood pressure and body fluid, which contributes to the pathophysiology of hypertension and cardiovascular/renal diseases. However, accumulating evidence has further revealed the complexity of this signal transduction system, including direct interactions with other receptors and proteins. This review focuses on recent research advances in RAAS with an emphasis on its receptors. RECENT
FINDINGS: Both systemically and locally produced angiotensin II (Ang II) bind to Ang II type 1 receptor (AT1R) and elicit strong biological functions. Recent studies have shown that Ang II-induced activation of Ang II type 2 receptor (AT2R) elicits the opposite functions to those of AT1R. However, accumulating evidence has now expanded the components of RAAS, including (pro)renin receptor, angiotensin-converting enzyme 2, angiotensin 1-7, and Mas receptor. In addition, the signal transductions of AT1R and AT2R are regulated by not only Ang II but also its receptor-associated proteins such as AT1R-associated protein and AT2R-interacting protein. Recent studies have indicated that inappropriate activation of local mineralocorticoid receptor contributes to cardiovascular and renal tissue injuries through aldosterone-dependent and -independent mechanisms. Since the mechanisms of RAAS signal transduction still remain to be elucidated, further investigations are necessary to explore novel molecular mechanisms of the RAAS, which will provide alternative therapeutic agents other than existing RAAS blockers.

Entities:  

Keywords:  (Pro)renin receptor (PRR); Angiotensin type 1 receptor (AT1R); Angiotensin type 2 receptor (AT2R); Mas receptor (MasR); Mineralocorticoid receptor (MR)

Year:  2020        PMID: 32114685     DOI: 10.1007/s11906-020-1028-6

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  11 in total

Review 1.  Lifestyle interventions for the prevention and treatment of hypertension.

Authors:  Pedro L Valenzuela; Pedro Carrera-Bastos; Beatriz G Gálvez; Gema Ruiz-Hurtado; José M Ordovas; Luis M Ruilope; Alejandro Lucia
Journal:  Nat Rev Cardiol       Date:  2020-10-09       Impact factor: 32.419

Review 2.  ATRAP, a receptor-interacting modulator of kidney physiology, as a novel player in blood pressure and beyond.

Authors:  Kouichi Tamura; Kengo Azushima; Sho Kinguchi; Hiromichi Wakui; Takahiro Yamaji
Journal:  Hypertens Res       Date:  2021-10-12       Impact factor: 3.872

3.  ATR1 Angiotensin II Receptor Reduces Hemoglobin S Polymerization, Phosphatidylserine Exposure, and Increases Deformability of Sickle Cell Disease Erythrocytes.

Authors:  Camila Cristina Guimarães-Nobre; Evelyn Mendonça-Reis; Lyzes Rosa Teixeira-Alves; Leandro Miranda-Alves; Clemilson Berto-Junior
Journal:  Cell Biochem Biophys       Date:  2022-09-29       Impact factor: 2.989

Review 4.  Recent advances in the management of secondary hypertension: chronic kidney disease.

Authors:  Takahiro Masuda; Daisuke Nagata
Journal:  Hypertens Res       Date:  2020-06-17       Impact factor: 3.872

5.  Clofibrate, a Peroxisome Proliferator-Activated Receptor-Alpha (PPARα) Agonist, and Its Molecular Mechanisms of Action against Sodium Fluoride-Induced Toxicity.

Authors:  Ademola Adetokunbo Oyagbemi; Olumuyiwa Abiola Adejumobi; Theophilus Aghogho Jarikre; Olumide Samuel Ajani; Ebunoluwa Racheal Asenuga; Idayat Titilayo Gbadamosi; Aduragbenro Deborah A Adedapo; Abimbola Obemisola Aro; Blessing Seun Ogunpolu; Fasilat Oluwakemi Hassan; Olufunke Olubunmi Falayi; Iyanuoluwa Omolola Ogunmiluyi; Temidayo Olutayo Omobowale; Oluwatosin Adetola Arojojoye; Olufunke Eunice Ola-Davies; Adebowale Benard Saba; Adeolu Alex Adedapo; Benjamin Obukowho Emikpe; Matthew Olugbenga Oyeyemi; Sanah Malomile Nkadimeng; Lyndy Joy McGaw; Prudence Ngalula Kayoka-Kabongo; Oluwafemi Omoniyi Oguntibeju; Momoh Audu Yakubu
Journal:  Biol Trace Elem Res       Date:  2021-04-24       Impact factor: 3.738

Review 6.  Fibrosis in Chronic Kidney Disease: Pathogenesis and Consequences.

Authors:  Sara Panizo; Laura Martínez-Arias; Cristina Alonso-Montes; Pablo Cannata; Beatriz Martín-Carro; José L Fernández-Martín; Manuel Naves-Díaz; Natalia Carrillo-López; Jorge B Cannata-Andía
Journal:  Int J Mol Sci       Date:  2021-01-02       Impact factor: 5.923

7.  AT1R/GSK-3β/mTOR Signaling Pathway Involved in Angiotensin II-Induced Neuronal Apoptosis after HIE Both In Vitro and In Vivo.

Authors:  Wei Si; Banghui Li; Cameron Lenahan; Shirong Li; Ran Gu; Hao Qu; Lu Wang; Jiapeng Liu; Tian Tian; Qian Wang; Xiao Hu; Gang Zuo
Journal:  Oxid Med Cell Longev       Date:  2020-12-22       Impact factor: 6.543

Review 8.  ACE2 imbalance as a key player for the poor outcomes in COVID-19 patients with age-related comorbidities - Role of gut microbiota dysbiosis.

Authors:  Sofia D Viana; Sara Nunes; Flávio Reis
Journal:  Ageing Res Rev       Date:  2020-07-16       Impact factor: 11.788

9.  Inhibition of Soluble Epoxide Hydrolase Attenuates Bosutinib-Induced Blood Pressure Elevation.

Authors:  Zhen Cui; Bochuan Li; Yanhong Zhang; Jinlong He; Xuelian Shi; Hui Wang; Yinjiao Zhao; Liu Yao; Ding Ai; Xu Zhang; Yi Zhu
Journal:  Hypertension       Date:  2021-10-04       Impact factor: 10.190

Review 10.  Evaluating the effects of sodium glucose co-transporter -2 inhibitors from a renin-angiotensin-aldosterone system perspective in patients infected with COVID-19: contextualizing findings from the dapagliflozin in respiratory failure in patients with COVID-19 study.

Authors:  Diala Alhaj Moustafa; Zainab Imran; Roua Ismail; Menatallah Rayan; Alain-Pierre Gadeau; Hussein Eldassouki; Nabeel Abdulrahman; Fatima Mraiche
Journal:  Mol Biol Rep       Date:  2022-01-31       Impact factor: 2.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.